Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

In This Article:

Candel Therapeutics
Candel Therapeutics

NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Elizabeth M. Jaffee, M.D., to the Company's Research Advisory Board (RAB). Dr. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, brings her extensive expertise to the RAB, which is important in light of the Company’s focus on borderline resectable pancreatic cancer.

Dr. Jaffee currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology, Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and Co-Director of the Gastrointestinal Cancers Program. Her research focuses on developing novel immunotherapies for the treatment and prevention of pancreatic cancer, with recent work concentrating on biomarker-driven immunotherapy clinical trials to understand complex inflammatory signals within the tumor microenvironment.

Dr. Jaffee is a past President of the American Association for Cancer Research (AACR) and served as co-chair of the Biden Moonshot Blue Ribbon Panel. She also currently serves as Chief Medical Advisor to the Lustgarten Foundation for Pancreatic Cancer Research and is the inaugural director of the Convergence Institute for Integrating Technologies and Computational Sciences at Johns Hopkins. She is a member of the National Academy of Medicine and previously served as chair of President Biden's Cancer Panel.

“We are delighted to welcome Dr. Jaffee to our high profile Research Advisory Board,” said Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO of Candel. “Her deep expertise in pancreatic cancer and immunotherapy aligns perfectly with our mission, particularly as we advance our CAN-2409 program in borderline resectable pancreatic cancer following our recent positive survival data. Dr. Jaffee's insights will help in guiding the design of our late-stage, potentially registrational clinical trial of CAN-2409 in borderline resectable pancreatic cancer.”

About Candel Therapeutics

Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and Herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. Recently, the Company announced positive, statistically significant topline data for CAN-2409 based on a large, randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in localized prostate cancer. In the Company’s randomized phase 2a clinical trial of CAN-2409 in borderline resectable pancreatic cancer, positive survival data showed notable improvement in estimated median overall survival of 31.4 months after experimental treatment with CAN-2409 plus standard of care versus only 12.5 months in the control group in patients with borderline resectable pancreatic cancer, who received only standard of care. Median survival post-progression was 21.2 months in patients who received CAN-2409 compared to 7.2 months in the control arm.